Amryt Pharma Share Discussion Threads

[ptgint] 31/3/2017 08:56

Thanks bigwavedave, that was very helpful. Much appreciated.

[jacksonpollack] 31/3/2017 07:35

And still no shareholder value. Plenty of bod value though as they continue to drain the account with their salaries

[bigwavedave] 30/3/2017 15:16

Does this answer your question?

[ptgint] 30/3/2017 15:11

When Fastnet O & G changed course to become AMYT the remaining O & G licences were ringfenced for the benefit of the shareholders at that time. With CF, who was deeply involved in the old company and now leaving AMYT how do the "old" shareholders now monitor what happens to those ringfenced licences I wonder ?

[bigwavedave] 30/3/2017 14:19

Start of Phase III Episalvan trial 'a momentous time in the history of Amryt' says CFO Rory Nealon

[papillon] 30/3/2017 11:55

Don't be so silly pottermagic2310. Read today's RNS, ffs. It highlights the fact that AMYT's EURO 20m facility from the EIB HASN'T BEEN TOUCHED YET!! Look at my previous posts today!

If you read the latest, recent, SHORE broker note (link previously posted on here) it assumes that AMYT will run out of cash in the middle of next year! That's around 15 months in the future. It will need to raise 15m before then.

I'm also filtering you pottermagic2310 as you don't appear to be bothered to read the RNS's, have approximately zero knowledge of the company and are unduly influenced by the pumpers and dumpers who populate these bb's.

[pottermagic2310] 30/3/2017 11:39

An actual Revenue Stream or 2 of some tangible value looks like good news to me.
Will it make continued good progress into the Autumn based on the known Costs vs the anticipated Revenue ?
Is there any substance to Posts above that this will be out of Funds in 2-3 months ?

[digadee] 30/3/2017 11:02

Revenue generating, derisked, EP trials underway and yet valued less than when it was fastnet which if you remember was just a cash shell. The market needs to wake up

[papillon] 30/3/2017 10:38

The following is from todays RNS. I'm posting it because steveo18 seems unwilling (or unable?) to read the RNS fully!!

"In December 2016, the Company entered into a EUR20 million facility agreement ("Facility") with the EIB on highly attractive terms for the Company. The Facility is significant because it provides non-dilutive funding that secures the Company's near and mid-term funding needs for its lead product, AP101. It also provides the funding required to progress the Company's acromegaly drug compound, AP102, through pre-clinical development. The facility from the EIB has not yet been drawn down."

EDIT: The good news is that they haven't touched that EUR 20m yet!!!!!!

[delta0091] 30/3/2017 10:32

“It has been a tremendously exciting year for the company. Amryt has made significant progress, both strategically and operationally,” said Joe Wiley, CEO of Amryt Pharma.

“A landmark point came in December 2016 when we reached an agreement to in-license the drug, Lojuxta, which treats a rare, life-threatening disorder, HoFH.
“The agreement has provided us with a cash generative product, with untapped sales potential, as well as a pan-European infrastructure which we can use for other drug assets. Building Lojuxta sales will be a major focus for us over 2017,” Mr Wiley added.

[delta0091] 30/3/2017 10:26

Revenues for the year to 31 December 2016 totalled €1,351,000 and comprised approximately one month's contribution from Lojuxta as well as well as a partial year's contribution from Imlan, the Company's derma-cosmetics range of products. The Lojuxta sales are for the period since the completion date on 2 December 2016 and totalled €775,000 in December. Very encouragingly, since the year end, Amryt recorded sales of €1,859,000 in January and February. Based on this, we expect Lojuxta to generate revenues of approximately €10.5 million on an annualised basis.

[digadee] 30/3/2017 09:41

Steve, sounds to me like you know jack about the company and more importantly zilch about the EIB loan facility that is in place.

[hutch_pod] 30/3/2017 09:39

The shore note posted above is helpful laying out the higher programme spend and EIB loan facility drawdown across 2017.

[steveo18] 30/3/2017 09:17

Theyre going to need it to avoid auditors qualifying the next set of accounts.

Definitely needs a placing before June i suspect

[digadee] 30/3/2017 09:17

Steve, u best sell up if you have any, looking very grim from your perspective.I on the other hand am well pleased with the results, better than expected. The bod really have made amazing progress, long may it continue. Revenues for lojuxta are very impressive indeed.

[icebreaker] 30/3/2017 09:15

Steveo18 - €20 Million EIB loan facility!

[steveo18] 30/3/2017 09:04

I see Development costs are capitalised as an intangible asset so the cash burn is even worse than the headline suggests

cash was £8m in december

Its March now and this looks like it will be running on empty before July

[steveo18] 30/3/2017 08:48

Market cap is £44m but it is burning cash at an alarming rate and i cannot see that being turned around before all the money is gone. As such the share price will track the cashburn all the way to zero. imho. Dyor

[icebreaker] 30/3/2017 07:48

Much better than expected results for me!

[icebreaker] 29/3/2017 17:42

I am assuming that tomorrow's figures up to 31 December 2016 are unlikely to show any meaningful revenue and to that extent, as long as there are no negative shocks the price is unlikely to fall. The loss should be well and truly factored in to the current share price! Is this a view shared by others?

[papillon] 29/3/2017 17:08

I've got both tjbird and runwaypaul on filter, alphabravo. tjbird was quoting figures from the SHORE note, but failing to mention the EURO 20m EIB facility. runwaypaul has followed me here because I filtered him on another advfn bb. He's just a very nasty piece of work. A gutless keyboard warrior.

[tjbird] 29/3/2017 15:03

runway,

have uyou seen these

Forecast LOSS for this year £18.4m

FORECAST LOSS £15.8m next year

Cash £10m so will be begging soon